Shinva Medical Instrument Co (600587) Fair Value & Analysis
Healthcare · CN · Market cap 7.7B CNY
Analysis
Shinva Medical Instrument Co (600587) currently trades at ¥12.02, while our model-based Fair Value estimate is ¥19.09 — implying the stock looks roughly 58.8% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Shinva Medical Instrument Co.,Ltd. provides medical devices, pharmaceutical equipment, medical services, and medical trade in the People's Republic of China. The company offers medical devices, including infection control instruments such as washing disinfection, sterilization, and consumables; radiotherapy equipment; and surgical instruments and biomedical consumables comprising standard, neuro, cardiovascular, ENT, imaging system laparoscopic, orthopedic, urological, intestinal and rectum, abdominal, plastic surgical, gynecologic and obstetric, micro, arthroscopic, ophthalmic, oral, stainless steel ware, sterilization container, and thoracoscopic small incision instruments. It also provides operating room integrated solutions, such as operating tables, medical ceiling pendants, surgical lights, and medical air disinfectors; dental units and sterilizers; and laboratory equipment, including washing equipment, air disinfectors, disinfection transfer chambers, bedding collection table…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.